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Abstract: Cutaneous metastases from primary internal malignancies represent 0.7-9% of patients with cancer. We report a 65- 
year-old	female	patient	referred	for	evaluation	of	normochromic	papules	on	the	trunk	and	upper	limbs	that	had	been	present	
for	three	months.	A	skin	biopsy	revealed	diffuse	cutaneous	infiltration	by	small	round	cell	tumors.	Immunohistochemistry	
was	positive	for	AE1/AE3,	CK7,	estrogen	receptor	and	mammaglobin.	The	final	diagnosis	was	cutaneous	metastasis	of	occult	
breast	cancer,	since	the	solid	primary	tumor	was	not	identified.	The	location	of	the	primary	tumor	can	not	be	determined	in	
5-10%	of	cases.	In	these	cases,	27%	are	identified	before	the	patient’s	death,	57%	at	autopsy,	and	the	remaining	16%	can	not	be
located.
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INTRODUCTION
Cutaneous	metastasis	 is	 defined	 as	 a	 neoplastic	 lesion	 af-
fecting the dermis or the subcutaneous tissue that originates from 
another primary tumor.1 Three basic patterns of metastasis mecha-
nisms are reported: mechanical tumor stasis (anatomical proximity 
and	lymphatic	drainage),	organ-specific	(selective	affinity	of	tumor	
cells	to	a	specific	organ),	and	nonselective	(independent	of	mechan-
ical	and	organ-specific	factors).1
Malignant	neoplasms	 that	most	 commonly	metastasize	 to	
the	 skin	 include	breast	 cancer,	 colon	cancer,	melanoma,	 lung	can-
cer,	 ovary	 cancer,	 sarcomas,	 and	 cervical	 cancer.1	 In	 most	 cases,	
cutaneous metastasis develops after the diagnosis of the primary 
internal	malignancy	and	late	in	the	course	of	the	disease.	An	inter-
val	of	five	years	from	the	initial	diagnosis	to	the	skin	metastases	is	
common.2	0.7-9%	of	patients	with	cancer	develop	skin	metastasis,	
which is considered a rare dermatological event.2,3	However,	with	
the	 increased	 incidence	of	 internal	 cancer,	dermatologists	may	be	
the	first	to	discover	the	disease.2	A	high	index	of	clinical	suspicion	is	
essential for the diagnosis of cutaneous metastatic lesions.3 
CASE 
Who was referred to our institution for evaluation of as-
ymptomatic	papules	and	nodules	on	the	trunk	and	upper	limbs	that	
had been present three months before the consultation. The patient 
was unable to report the initial morphology or changing pattern of 
the	lesions.	She	also	reported	weight	loss,	which	was	not	measured,	
and	asthenia.	Remarkable	personal	history	included	anemia	treated	
with ferrous sulfate and a sectorectomy of a benign left breast lump 
eight	years	before	–	which	was	anatomopathologically	confirmed.	
The	patient	was	G4P3A1	and	had	been	in	menopause	for	16	years.	
She	denied	alcohol	abuse,	smoking,	or	remarkable	family	history.
On	physical	examination,	 the	patient	was	emaciated,	pale	
(3+/4+),	presented	with	normochromic	rounded	papules	and	nod-
ules,	with	well-defined	regular	edges	and	fibroelastic	consistency.	
The	lesions	were	slightly	movable,	0.3-1	cm	in	diameter,	located	on	
the	arm	root,	chest	and	back.	We	also	observed	a	 linear	pearl-col-
ored	scar	on	the	left	breast	(Figures	1-3).
Additional	tests	were	performed	(Chart	1).	Histopathology	
of	two	areas	of	the	skin	showed	a	diffuse	round	cell	infiltration	in	
the	dermis	and	part	of	the	hypodermis,	sparing	the	epidermis,	di-
vulsing the collagen bundles. The lesions were isolated or linearly 
arranged	in	rows,	printing	an	irregular	pattern	(Figure	4).	Immuno-
histochemical examination showed strong and diffuse positivity for 
AE1/AE3,	favoring	the	diagnosis	of	carcinoma,	and	negative	results	
for	S100	protein	and	leukocyte	common	antigen	(LCA).	Melanoma	
and hemolymphatic cancers were ruled out. Positive multigene 
panel	 showed	positivity	 to	CK7,	mammaglobin,	 and	 estrogen	 re-
ceptor,	suggesting	the	breast	tissue	as	the	primary	site.	Other	mark-
ers are shown in Table 1. The patient was referred to a gynecologist 
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who, after a clinical evaluation, opted for a biopsy of axillary lymph 
nodes on the left side: four lymph nodes with metastatic carcinoma.
Given the clinical findings and laboratory test results, a final 
diagnosis of cutaneous metastasis of occult breast cancer was made 
since the primary solid tumor was not detected by any other exam-
ination. We reviewed the slides of the sectorectomy performed in 
Figure 1: 
Papules and nodules 
on the left arm root
Figure 2: 
Papules and nodules 
on the back
Figure 3: 
Scar of pre-
vious sec-
torectomy
Figure 4: Skin: diffuse neoplastic infiltration in the dermis (hema-
toxylin and eosin; x200); Inset: higher magnification showing small 
round cell tumors 
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chart 1: Results of additional tests and complementary im-
munohistochemistry
Blood count and biochemistry
•Hgb:	7.2	g%,	PCV:	24%,	MCV:	116	pg
•ESR: 135mm
•CA	125:	63.4	(=32)
•CEA:	12.1	(=9)
Imaging exams
•Thoracic CT: axillary lymph node on the left;
•	Endoscopy:	erosive	esophagitis	grade	a	(LA	Classification).	
Positive H. pylori
•	Normal	chest	X-ray,	mammography,	tomography	of	the	abdo-
men/pelvis,	and	colonoscopy.
Immunohistochemistry - Other Markers
•TIF-1,	CK20,	CDX2,	WT1,	CD43,	p63,	C-kit	and	CD34:	negative.
2005	and	identified	no	neoplasias.	The	patient	was	then	referred	to	
an	oncologist	for	follow-up	and	chemotherapy.	Unfortunately,	she	
died 10 months after the diagnosis.
DISCUSSION
The	frequency	of	cutaneous	metastases	has	increased	due	to	
higher cancer survival rates and better therapeutic alternatives.4 The 
identification	of	both	the	skin	cancer	and	the	primary	tumor	can	be	
difficult	due	to	the	great	variability	in	clinical	course.	After	a	cancer	
treatment,	metastases	can	be	the	first	sign	of	relapse,	having	a	sig-
nificant	prognostic	value	for	substantially	reducing	survival	rates.2
Metastases	are	more	common	in	older	people.	A	skin	biopsy	
in patients with cancer should be considered in case of early or sud-
den	onset,	delayed	healing,	bleeding	tendency,	or	vascular	appear-
ance of the lesions that do not resolve after treatment.2 
About	60%	of	the	metastatic	cancers	are	adenocarcinomas.	
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Malignant	 neoplasms	 that	most	metastasize	 include	 breast,	 lung,	
and	gastrointestinal	tract	cancers.	In	patients	under	50	years	of	age,	
metastasis	is	often	linked	to	malignant	melanoma.	In	pediatric	pa-
tients,	although	infrequent,	metastasis	are	usually	caused	by	neuro-
blastomas	and	leukemias.5,6
The	most	 common	sites	of	metastasis	 (75%)	are	 the	 scalp,	
navel,	chest	wall,	and	abdomen,	and	in	75%	of	women,	they	occur	
on	the	chest	and	abdomen.	In	women,	the	most	common	primary	
malignancy	is	breast	cancer	(69%),	which	tends	to	metastasize later to 
the anterior thoracic wall.3,7	Van	den	Hurk	et al.	(2011)	analyzed	me-
tastases patterns in patients diagnosed with primary breast cancer 
and	found	that	skin	metastases	often	appear	later	than	metastases	
in other areas.8
Although	metastasis	 clinical	 presentation	 is	 variable,	 it	 is	
more	 frequently	characterized	as	normochromic	or	brownish	firm	
nodules with sudden onset. Lesions can be painless or associated 
with	pain	and	sensitivity,	with	 fast	 initial	growth	and	subsequent	
stabilization.	They	may	be	solitary	or	multiple,	with	inflammatory	
or	sclerotic	aspects,	and	may	retract	the	skin.2,9 Extensive cutaneous 
involvement of metastatic breast cancer may mimic cellulitis or a 
breast-plate	of	armor	(“en	cuirasse”	pattern).3 
Differential diagnosis consists of other similar histologically 
lesions,	benign,	 inflammatory,	or	malignant,	 of	different	prognos-
tics.10 Breast	 cancer	 immunohistochemistry	 reveals	 a	 cytokeratins	
pattern	of	CK7+/CK20-.	Estrogens	and	progesterone	receptors	are	
markers	that	increase	the	detection	sensitivity	of	breast	cancers.7
Despite	the	imaging	techniques	and	immunohistochemistry,	
the primary tumor location cannot be determined in 5-10% of cases. 
In	general,	patients	with	metastatic	carcinoma	of	unknown	primary	
site	have	a	worse	prognosis.	In	these	patients,	the	primary	tumor	is	
only	identified	in	27%	of	cases	before	death;	57%,	at	autopsy;	and	for	
the	remaining	16%,	primary	tumor	can	not	be	identified.8 q
